"From the supply of COVID-19 vaccines that reached 225.4 million doses, Bio Farma has distributed as many as 141.4 million doses of vaccines from January to the first week of September 2021," Corporate Secretary and Bio Farma spokesperson Bambang Heriyanto stated on Tuesday.
Based on a report by the Committee for COVID-19 Handling and National Economic Recovery (KPCPEN), Indonesia received 50 batches of vaccines until the first week of September 2021.
The duo vaccine arrivals took place in December 2020, with three million doses of the vaccine in the form of finished product from Sinovac. As many as 16.5 million doses of Sinovac vaccine in raw material form arrived in January and 11 million doses of Sinovac in raw material form arrived in February.
Batches arrived thrice in March comprising 26 million doses of Sinovac in raw material form and 1.1 million doses of AstraZeneca in the form of finished product.
The frequency of shipments increased four folds, with arrivals in April comprising 12 million doses of Sinovac in raw material form, 3.8 million doses of AstraZeneca in finished form, and 482 thousand doses of Sinovac in finished form.
A total of five additional vaccine arrivals occurred in May comprising 16 million doses of Sinovac in raw material, 1.3 million doses of AstraZeneca in finished form, and 517 thousand doses of Sinopharm in finished form.
Another four arrivals were recorded in June, with 24 million doses of Sinovac in raw material form, one million doses of Sinopharm in finished form, and 1.8 million doses of AstraZeneca in finished form.
The biggest vaccine delivery occurred in July 2021, with 14 arrivals with a total acquisition of 56.1 million doses of vaccine in finished and raw material form. In August 2021, Indonesia also received 14 vaccine arrivals, totaling more than 43 million doses in finished and raw material form.
As of the first week of September, Indonesia had received vaccines in five stages: 1.2 million doses of AstraZeneca in finished form, five million doses of Sinovac in finished form, and 1.1 million doses of Pfizer in finished form.
"In September 2021, Indonesia is estimated to receive an additional 16.5 million vaccine stock for Bio Farma's COVID-19 vaccine, which will be filled and finished at Bio Farma's production facilities," Heriyanto remarked.
Vaccines arriving at the Soekarno-Hatta Airport will pass through a quarantine stage and a sampling process before acquiring a lot release from the Drug and Food Control Agency (BPOM) to then be distributed to 34 provinces in Indonesia.
Vaccines that have been distributed comprise three million doses of CoronaVac 1, 93.06 million doses of Bio Farma, AstraZeneca under the Covax scheme, 16.8 million doses through business transactions and grants, 7.6 million doses of Moderna, 20.4 million doses of CoronaVac 2, and 499.9 thousand doses from Sinopharm under a grant.
For the remaining stock at Bio Farma as of September 5, Heriyanto noted that as many as 14.9 million doses will be distributed immediately after receiving a request from the Indonesian Ministry of Health.
"In September 2021, in addition to receiving further two doses of the CoronaVac vaccine in the form of finished product of the 25 million doses of vaccine, Indonesia will also receive additional vaccines from the Covax/Gavi multilateral scheme, bilateral and other bilateral donations," he stated.
Heriyanto estimates that the total stock availability of vaccines in Indonesia for September's supply requirements is expected to reach more than 70 million doses.
Related news: Indonesia ranks sixth in world's COVID-19 vaccination rate list
Related news: Indonesia receives five million Sinovac vaccine doses
Related news: Indonesia secures 225.4 million vaccines as of Monday; Minister